结构性心脏病中的飞化物:超越CAST试验的当代重新评估
Davide Genovese1, Micheal Salama1, Donatella Ruggiero2
1Cardiology Unit, Cardio-Neuro-Vascular Department, Ca' Foncello Hospital, Treviso, Italy.
Heart rhythm
|August 27, 2025
概括
对于某些有结构性心脏病 (SHD) 的患者来说,Flecainide可能是安全的,挑战过去的禁忌. 新证据表明个性化使用,超出心律失常抑制试验 (CAST) 的发现.
科学领域:
- 心脏病学
- 药理学
- 临床医学
背景情况:
- 由于心律失常抑制试验 (CAST) 的发现,在结构性心脏病 (SHD) 中限制了flekainide的使用.
- 在心肌梗塞后的患者中,CAST试验显示死亡率增加,导致广泛的禁忌.
- 这导致了弗莱卡尼德作为抗心律失常药物的潜在使用不足.
研究的目的:
- 审查和挑战CAST关于飞胺安全性的过度概括.
- 探索支持在特定SHD群体中使用flekainide的新兴证据.
- 在心脏病学中倡导患者特异性治疗方法.
主要方法:
- 关于SHD的现有文献和观察性研究的审查.
- 对不同患者群体的安全性和疗效数据的分析.
- 基于CAST试验结果的历史安全教条的批评.
主要成果:
- 观察数据表明,在特定的冠状动脉疾病患者中,包括那些冠状动脉疾病稳定且心室功能保持不变的患者中,flekainide可能是安全和有效的.
- 在心律失常性右心室心肌病和PVC诱导的心肌病等心肌病中,弗莱卡因具有前景.
- 目前的证据支持细微的,个性化的 flecainide 处方方法.
结论:
- 在SHD中使用 flecainide的禁忌可能过于广泛,并且基于误解的数据.
- 如果明智地使用, 弗莱卡尼德对于特定的患者群体可能是一个有价值的选择.
- 需要进一步的随机对照试验来证实这些发现并重新定义 flecainide 的作用.
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K
01:30Acute Coronary Syndrome III: Diagnostic Studies
23
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
23
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
57
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
57
01:25Dysrhythmias VI: Management of Dysrhythmias
106
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
106
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
845
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
845